Perseus ProteomicsPerseus Proteomics Inc.4882東証グロース医薬品FY ending Mar 2026, non-consolidated, J-GAAP

Perseus Proteomics FY ending Mar 2020 results

Perseus Proteomics brought in ¥85.8M in revenue.

It lost about ¥947 for every ¥100 of sales at the operating level.

Where the money goes

For every ¥100 Perseus Proteomics sells, how much goes where, and how much is kept.

FY ending Mar 2020

Margin funnel (derived from reported values)Gross margin 92.6% → Operating margin -947.3% → Net margin -981.5%

Show source documents (3)

EDINET (FSA Japan)
有価証券報告書－第24期(2023/04/01－2024/03/31)
ID S100TOCF2024-06-20Open
EDINET (FSA Japan)
有価証券報告書－第22期(令和3年4月1日－令和4年3月31日)
ID S100OCLP2022-06-23Open
EDINET (FSA Japan)
有価証券報告書－第21期(令和2年4月1日－令和3年3月31日)
ID S100LP5E2021-06-25Open

Extracted from XBRL: 33 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.